Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus Clinical Trial

Official title:

Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02274740
• Other study ID #: LIXISL07016
• Secondary ID: U1111-1153-3774
• Status: Terminated
• Phase: Phase 2
• First received: October 17, 2014
• Last updated: January 27, 2017
• Start date: April 2015
• Est. completion date: August 2015

Study information

• Verified date: January 2017
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides.

Secondary Objectives:

The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL) oxidation.

The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent diabetes mellitus (NIDDM) and obesity.

The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.

Description:

Maximum study duration of approximately 2.5 months (study treatment) ± 2 days Day 0 (baseline) plus a 10-week open-label, active-controlled treatment period (Final/End-of-treatment Visit).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria:

Male and female patients, 18-70 years of age.

Diagnosis of Type 2 diabetes treated with metformin and obesity (body mass index [BMI] >30 kg/m^2) and the following other abnormalities:

• Abdominal obesity (waist circumference >102 cm in men and >88 cm in women). According to National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III (2001).

• Glycated hemoglobin A1c (HbA1c) =7 and =8.5% (after Sponsor approval providers might reasonably suggest more stringent A1c goals [such as 6.5%] for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment. Appropriate patients might include those with short duration of diabetes, long life expectancy, and no significant cardiovascular disease).

• Hypertriglyceridemia (fasting triglyceride levels between 150 mg/dL and 600 mg/dL, cholesterol <300 mg/dL. In order to exclude patients who might be suffering from a primitive dyslipidemia).

• Low high-density lipoprotein (HDL) cholesterol (serum HDL-cholesterol <40 mg/dL in men and <50 mg/dL in women).

Written informed consent.

Exclusion criteria:

Smoking. Thyroid disease even if under appropriate hormonal replacement therapy or thyroid suppressant (Thyroid Stimulating Hormone [TSH] >5 mU/L with clinical symptoms of hypothyroidism).

Hepatic disease (Aspartate Aminotransferase [ASAT] or Alanine Aminotransferase [ALAT] >2 times the upper limit of normal).

Renal disease (serum creatinine >1.7 times the upper limit of normal). A history of coronary heart disease, cerebrovascular disease, or peripheral arterial disease in the 6 months before enrollment.

History of malignancies. Use of lipid lowering therapy. Systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg. Triglycerides >600 mg/dL. History of chronic pancreatitis or of idiopathic acute pancreatitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type II Diabetes Mellitus

Intervention

Drug:
• LIXISENATIDE AVE0010
Pharmaceutical form:solution Route of administration: subcutaneous
• metformin
Pharmaceutical form:tablet Route of administration: oral

Locations

Country	Name	City	State
Italy	TBD	TBD

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)		After 10 weeks of treatment
Secondary	Change from baseline in plasma triglyceride		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in plasma cholesterol		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in APO B48		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in free fatty acid levels		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in lipoprotein distribution		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in LDL oxidation		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in postprandial plasma glucose		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in insulin		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in C-peptide		2 days after the basal test and after 10 weeks of treatment
Secondary	Change from baseline in low grade inflammation (cytokines and stress oxidative markers)		2 days after the basal test and after 10 weeks of treatment
Secondary	Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction		2 days after the basal test and after 10 weeks of treatment